Cady, Roger, M.D.

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Cady, Roger, M.D. sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 9 completed later-stage tilt top decile by trial count

Cady, Roger, M.D.: 12 sponsored US clinical trials, none currently recruiting.

Cady, Roger, M.D. sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 9 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Menstrual Migraine, with 1 trials.

Top-decile sponsor footprint

Cady, Roger, M.D. ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

TERMINATED Phase 2

Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache

NCT02381795
COMPLETED Phase 2

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
COMPLETED Phase 2

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655
COMPLETED Phase 4

Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

NCT02037425
COMPLETED Phase 4

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
COMPLETED Phase 4

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
COMPLETED Phase 4

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

NCT01300546
COMPLETED Phase 4

Treximet in the Treatment of Chronic Migraine

NCT01090050
COMPLETED Phase 4

Calcitonin Gene-related Peptide Levels in Chronic Migraine

NCT01071096
TERMINATED Phase 4

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT01053507
COMPLETED Phase 4

"Completeness of Response" Following Treatment With Treximet™ for Migraine

NCT00893737
TERMINATED Phase 4

Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT00487578

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 4 9

Therapeutic Areas

Menstrual Migraine 1
Chronic Migraine 1

How the Cady, Roger, M.D. archive is shaped

12 indexed studies, none listed as recruiting (0% open); 9 completed (75%).

Phase mix: 9 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Menstrual Migraine (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cady, Roger, M.D.: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cady, Roger, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Cady, Roger, M.D.Alachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Cady, Roger, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cady, Roger, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cady, Roger, M.D. page

12 registered trials is a research-attention snapshot, not an endorsement of Cady, Roger, M.D. or any single study.

  • None of Cady, Roger, M.D.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Menstrual Migraine is the condition Cady, Roger, M.D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Menstrual Migraine trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cady, Roger, M.D. pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.